Clinical trials: Pegfilgrastim
Non-Hodgkin's Lymphoma
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of PBPCs for autologous…
- Trial name
- NCT00117455
- Testing
- pegfilgrastim, filgrastim
- Sponsor
- Amgen
Pancreatic Adenocarcinoma
Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
The purpose of this study is to see how well electrochemotherapy works at treating people with Stage III pancreatic adenocarcinoma. Electrochemotherapy is a treatment that combines electroporation and chemotherapy administration.
- Trial name
- NCT02592395
- Testing
- FOLFIRINOX, Electroporation
- Sponsor
- The University of Texas Health Science Center, Houston
Healthy
Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of CHS-1701 (Coherus pegfligrastim) or 6mg SC dose of…
- Trial name
- NCT02650973
- Testing
- CHS-1701, Pegfilgrastim
- Where
- 4 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Coherus Oncology, Inc.
Febrile Neutropenia, Non-myeloid Malignancy
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
This is a multicenter, prospective, observational cohort registry in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy who are considered to be at high risk for developing febrile neutropenia (FN).
- Trial name
- POEM (NCT04662892)
- Testing
- Pegfilgrastim-Cbqv
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Coherus Oncology, Inc.
Breast Neoplasms
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round are randomly assigned to either the control or experimental arm.
- Trial name
- NEUTHREE (NCT05949333)
- Testing
- Eflapegrastim
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Eunseong Medical Foundation Good GANG-AN HOSPITAL
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma…
- Trial name
- NCT02142049
- Testing
- Ibrutinib, DA-EPOCH-R, Lenalidomide
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT00334815
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 61 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.
- Trial name
- NCT00283621
- Testing
- Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554463
- Testing
- Filgrastim, Pegfilgrastim, Etoposide
- Where
- 14 sites in United States
- Volunteers
- 5 people
- Sponsor
- Radiation Therapy Oncology Group
Healthy
Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects
The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of MSB11455 and Neulasta in healthy adult subjects.
- Trial name
- NCT03251248
- Testing
- MSB11455, Neulasta
- Where
- 2 sites in Australia
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Neutropenia, Severe Chronic
ANF-Rho in the Treatment of Chronic Neutropenia
A 6 month safety, tolerability, efficacy and pharmacokinetic study with ANF-Rho to treat patients with chronic neutropenia.
- Trial name
- NCT02533362
- Testing
- ANF-Rho
- Sponsor
- Prolong Pharmaceuticals
Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer.
- Conditions
- Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
- Trial name
- NCT00304070
- Testing
- Cisplatin, Conventional Surgery, Doxorubicin Hydrochloride
- Where
- 91 sites in United States, Australia and 2 more
- Volunteers
- 78 people
- Sponsor
- Children's Oncology Group
Diffuse Large B-Cell Lymphoma
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)
- Trial name
- DLBCL (NCT02531308)
- Testing
- Metformin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center
Lymphoma
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, etoposide phosphate, dexamethasone, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- Protocol-B (NCT00074178)
- Testing
- filgrastim, pegfilgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- OHSU Knight Cancer Institute
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02181218
- Testing
- Romidepsin, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast).
- Trial name
- NCT00777673
- Testing
- Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Cancer Institute
Lymphoma
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
RATIONALE: Herpesvirus is found in the cancer cells of patients with primary effusion lymphoma. Antiviral drugs, such as zidovudine and valganciclovir, may be able to act against the herpesvirus in the cancer cells to help kill…
- Trial name
- NCT00217503
- Testing
- bevacizumab, filgrastim, pegfilgrastim
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00310089
- Testing
- filgrastim, pegfilgrastim, cediranib maleate
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse, Large B-Cell, Lymphoma
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.
- Trial name
- GIOTTO (NCT02374424)
- Testing
- GA101_DHAP
- Where
- 10 sites in Italy
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Multiple Myeloma
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant…
- Trial name
- NCT05130827
- Testing
- Plinabulin
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center